フォロー
Annette Vangsted
Annette Vangsted
Associate professor på K'benhavns universitet
確認したメール アドレス: regionh.dk
タイトル
引用先
引用先
Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA‐DR/low Myeloid‐Derived Suppressor Cells and Decreased Level of Dendritic Cells in …
MK Brimnes, AJ Vangsted, LM Knudsen, P Gimsing, AO Gang, ...
Scandinavian journal of immunology 72 (6), 540-547, 2010
2692010
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
P Moreau, SK Kumar, J San Miguel, F Davies, E Zamagni, N Bahlis, ...
The Lancet Oncology 22 (3), e105-e118, 2021
2032021
Genome-wide association study identifies multiple susceptibility loci for multiple myeloma
JS Mitchell, N Li, N Weinhold, A Försti, M Ali, M Van Duin, G Thorleifsson, ...
Nature communications 7 (1), 12050, 2016
1842016
Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
E Terpos, M Engelhardt, G Cook, F Gay, MV Mateos, ...
Leukemia 34 (8), 2000-2011, 2020
1352020
Effect of pamidronate 30 mg versus 90 mg on physical function in patients with newly diagnosed multiple myeloma (Nordic Myeloma Study Group): a double-blind, randomised …
P Gimsing, K Carlson, I Turesson, P Fayers, A Waage, A Vangsted, ...
The lancet oncology 11 (10), 973-982, 2010
1352010
Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma
M Went, A Sud, A Försti, BM Halvarsson, N Weinhold, S Kimber, ...
Nature communications 9 (1), 3707, 2018
1132018
Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium
R Ríos, CB Lupiañez, D Campa, A Martino, J Martínez-López, ...
Endocrine-related cancer 22 (4), 545-559, 2015
982015
Variants in ELL2 influencing immunoglobulin levels associate with multiple myeloma
B Swaminathan, G Thorleifsson, M Jöud, M Ali, E Johnsson, R Ajore, ...
Nature communications 6 (1), 7213, 2015
892015
Smoldering multiple myeloma risk factors for progression: a Danish population‐based cohort study
R Sørrig, TW Klausen, M Salomo, AJ Vangsted, B Østergaard, ...
European journal of haematology 97 (3), 303-309, 2016
682016
Causes of early death in multiple myeloma patients who are ineligible for high-dose therapy with hematopoietic stem cell support: A study based on the nationwide Danish Myeloma …
MO Holmström, P Gimsing, N Abildgaard, NF Andersen, C Helleberg, ...
American journal of hematology 90 (4), E73-4, 2015
612015
Immunochemical Detection of a Small Cell Lung Cancer-associated Ganglioside (FucGM1) Antigen in Serum
AJ Vangsted, H Clausen, TB Kjeldsen, T White, B Sweeney, S Hakomori, ...
Cancer research 51 (11), 2879-2884, 1991
611991
Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow …
A Vangsted, P Gimsing, TW Klausen, BA Nexø, H Wallin, P Andersen, ...
International journal of cancer 120 (5), 1036-1045, 2007
582007
Oxytocin and vasopressin binding sites in human and bovine ovaries
AR Fuchs, O Behrens, H Helmer, A Vangsted, M Ivanisevic, J Grifo, ...
American journal of obstetrics and gynecology 163 (6), 1961-1967, 1990
561990
Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma
P Sonneveld, MA Dimopoulos, M Boccadoro, H Quach, PJ Ho, M Beksac, ...
New England Journal of Medicine 390 (4), 301-313, 2024
552024
The impact of comorbidity on mortality in multiple myeloma: a Danish nationwide population‐based study
H Gregersen, AJ Vangsted, N Abildgaard, NF Andersen, RS Pedersen, ...
Cancer medicine 6 (7), 1807-1816, 2017
542017
Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population
R Sørrig, TW Klausen, M Salomo, AJ Vangsted, UC Frølund, KT Andersen, ...
PLoS One 12 (12), e0188988, 2017
512017
Phase I study of venetoclax plus daratumumab and dexamethasone, with or without bortezomib, in patients with relapsed or refractory multiple myeloma with and without t (11; 14)
NJ Bahlis, R Baz, SJ Harrison, H Quach, SJ Ho, AJ Vangsted, T Plesner, ...
Journal of Clinical Oncology 39 (32), 3602, 2021
492021
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients
E Ziv, E Dean, D Hu, A Martino, D Serie, K Curtin, D Campa, B Aftab, ...
Nature communications 6 (1), 7539, 2015
492015
First-in-human phase I study of the novel CELMoD agent CC-92480 combined with dexamethasone (DEX) in patients (pts) with relapsed/refractory multiple myeloma (RRMM).
PG Richardson, AJ Vangsted, K Ramasamy, S Trudel, J Martínez, ...
Journal of Clinical Oncology 38 (15_suppl), 8500-8500, 2020
462020
The Danish national multiple myeloma registry
P Gimsing, MO Holmström, TW Klausen, NF Andersen, H Gregersen, ...
Clinical epidemiology, 583-587, 2016
462016
現在システムで処理を実行できません。しばらくしてからもう一度お試しください。
論文 1–20